The Science Behind Fat Volume Reduction
RZL-012 kills fat cells with subcutaneous injections
RZL-012, our novel synthetic small molecule (NCE) kills fat cells when injected into subcutaneous fat. It is the first and only injectable drug shown to significantly and sustainably shrink the size of Lipomas in Dercum’s Disease, reduce the volume of abdominal fat (body contouring) and submental fullness (double chin). In vitro studies show that RZL-012 reduces the ability of fat cells to accumulate or store fat
How does RZL-012 work?
RZL-012 is administered by several injections delivered in a single injection session.
Once injected, RZL-012 triggers immediate fat cell death, followed by a transient inflammatory process that lasts about a month during which necrotic fat tissue is replaced by fibrotic tissue. This results in a significant long-term, sustained shrinkage of fat tissue.
How does RZL-012 work?
RZL-012 is administered by several injections delivered in a single injection session.
Once injected, RZL-012 triggers immediate fat cell death, followed by a transient inflammatory process that lasts about a month during which necrotic fat tissue is replaced by fibrotic tissue. This results in a significant long-term, sustained shrinkage of fat tissue.
Single injection session
Subcutaneous injections performed in a single session
Significant fat reduction
20% for abdominal fat; 50% reduction in lipoma height
Results within 1 month
Treatment effect evident at 1-month post treatment
Safe and well-tolerated
Mild side effect profile
Extensive applications
Can be applied to various body areas